On May 14, 2025, Cantor Fitzgerald analyst Kristen Kluska reiterated an "Overweight" rating for Capricor Therapeutics (CAPR, Financial). The analyst maintained the price target at $30.00 USD, unchanged from the prior target.
The reiteration of the "Overweight" rating suggests that Capricor Therapeutics (CAPR, Financial) continues to be regarded as a promising investment. The consistent price target highlights the analyst's confidence in the company's performance and potential growth in the foreseeable future.
Capricor Therapeutics (CAPR, Financial) remains a focus for investors as the company progresses with its therapeutic developments. With the support of analysts like those from Cantor Fitzgerald, the stock is expected to attract ongoing interest from the market.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for Capricor Therapeutics Inc (CAPR, Financial) is $43.71 with a high estimate of $77.00 and a low estimate of $25.00. The average target implies an upside of 465.73% from the current price of $7.73. More detailed estimate data can be found on the Capricor Therapeutics Inc (CAPR) Forecast page.
Based on the consensus recommendation from 7 brokerage firms, Capricor Therapeutics Inc's (CAPR, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Capricor Therapeutics Inc (CAPR, Financial) in one year is $15.92, suggesting a upside of 106.03% from the current price of $7.727. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Capricor Therapeutics Inc (CAPR) Summary page.
